Current trends in management of hepatitis B virus reactivation in the biologic therapy era

Hepatitis B virus (HBV) reactivation represents an emerging cause of liver disease in patients undergoing treatment with biologic agents. In particular, the risk of HBV reactivation is heightened by the use monoclonal antibodies, such as rituximab (anti-CD20) and alemtuzumab (anti-CD52) that cause p...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Mastroianni, Claudio M, Lichtner, Miriam, Citton, Rita, Borgo, Cosmo Del, Rago, Angela, Martini, Helene, Cimino, Giuseppe, Vullo, Vincenzo
Формат: Artigo
Язык:Inglês
Опубликовано: Baishideng Publishing Group Co., Limited 2011
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3198017/
https://ncbi.nlm.nih.gov/pubmed/22025876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v17.i34.3881
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы